Release Date: August 29, 2025
CME Track Expiration Date: August 29, 2026
Pharmacist Track Expiration Date: December 31, 2026
Activity Overview
Schizophrenia represents a major psychiatric disorder characterized by symptoms that frequently compromise daily functioning and diminish overall quality of life. While effective management can lead to improved patient outcomes, many individuals continue to struggle with persistent or residual symptoms, medication adherence challenges, and adverse drug reactions. In particular, poor adherence to oral antipsychotic treatment increases the likelihood of symptom recurrence and psychiatric hospitalization. To address these challenges, long-acting injectable (LAI) antipsychotic formulations have been developed that offer advantages, such as eliminating the need for daily medication administration, maintaining more stable drug levels in the bloodstream, and facilitating consistent clinical oversight.
This educational program brings together clinical experts to examine how long-acting injectable antipsychotics can be effectively utilized in schizophrenia treatment, emphasizing their therapeutic benefits and safety profiles while exploring optimal strategies for incorporating these medications into personalized patient care approaches.
This educational activity is an archive of the live virtual symposium held on July 12, 2025.
Target Audience
This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, pharmacists, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review relevant clinical characteristics of long-acting injectable agents for schizophrenia
- Integrate long-acting injectable medications into individualized management plans for patients with schizophrenia
Gus Alva, MD, DFAPA
Assistant Professor, Department of Psychiatry and Neuroscience
University of California Riverside Medical School
Riverside, CA
Pacific Neuropsychiatric Specialists
Medical Director, ATP Clinical Research
Medical Director, Senior Brain Health, Hoag Hospital,
Newport Beach, CA
Disclosures: Grant/Research Support: AbbVie, Accera, Allergan, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech; Consultant and Speaker’s Bureau: AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech.
Ilan Melnick, MD
Assistant Professor, Department of Psychiatry
Florida International University School of Medicine
Chief Medical Officer, Passageway Residence of Dade County
Miami, FL
Disclosures: Advisory Boards: AbbVie, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Idorsia, Indivior, Intra-Cellular Therapies, Janssen, Lilly, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva; Consultant and Speaker’s Bureau: AbbVie, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Idorsia, Indivior, Intra-Cellular Therapies, Janssen, Lilly, Lundbeck, Merck, Neurocrine, Otsuka, Sage, Sunovion, Takeda, Teva, Vanda Pharmaceuticals.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians’ Education Resource®, LLC, (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC has approved this knowledge-based activity for 1.00 ACPE CE hours 0661-0000-25-009-H01-P. Eligibility for credits requires full engagement with the enduring activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre- and post- session questions, and the post activity evaluation. This UAN # expires December 31, 2026.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Teva and Johnson & Johnson.